Use of rosuvastatin lactols as medicaments

A method of treating a condition comprising:

• administering an effective amount of a compound of Formula I
• or pharmaceutically acceptable salts or solvates thereof to inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase),
• wherein the condition is selected from the group consisting of:
• hypercholesterolemia, atherosclerosis, hyperlipidemia, coronary heart disease, myocardial infarction, stroke, and peripheral artery disease,
• further wherein:
• R1 and R4 are independently selected from the group consisting of:
• hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, aryl, C1-4 alkyl aryl, heterocyclyl, and C1-4 alkyl heteroaryl;
• R2 is —S(O)2R9 wherein R9 is C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkyl aryl or aryl;
• R3 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl or aryl;
• R5 and R6 are independently selected from the group consisting of:
• hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C3-6 cycloalkyl, aryl, C1-6 alkyl aryl, C1-6 alkanoyl aryl, heteroaryl, C1-6 alkanoyl heteroaryl and C1-6 alkyl heteroaryl;
• provided always that both R5 and R6 are not hydrogen;
• R7 and R8 are independently selected from the group consisting of:
• H, C1-4 alkyl and halo;
• X is —(CRaRb)m(CRa═CRb)n(CRaRb)o where Ra and Rb are independently selected from the group consisting of:
• H, methyl, ethyl and halo and m, n, and o are independently 0, 1, 2, or 3 provided that m+n+o is not more than 3;
• and wherein each of the above groups R1 to R9 may, where chemically possible, be independently optionally substituted by from 1 to 5 groups chosen independently at each occurrence from the group consisting of:
• halo, C1-3 alkyl, halo C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkoxy, hydroxy, and cyano.